Inventor profile of:

Seppo YLA-HERTTUALA

City:

Kuopio

Country:

Finland

Published Applications:

46

Last publication date:

2025-05-22

Top Assignees for applications by Seppo YLA-HERTTUALA

The entities that hold a legal rights for patent applications filed by inventor YLA-HERTTUALA Seppo:

Recent patent applications by YLA-HERTTUALA Seppo

Seppo YLA-HERTTUALA from Kuopio, FI has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-05-22
US20250163519A1
Chemistry; metallurgy

GENE THERAPY VECTOR CONTAMINATION ASSAY

#2 | 2023-07-27
US20230235341A1
Chemistry; metallurgy

ANTI-ANGIOGENIC GENE THERAPY WITH SOLUBLE VEGF RECEPTORS -1, -2 AND -3 TOGETHER WITH PACLITAXEL PROLONGS SURVIVAL OF MICE WITH HUMAN OVARIAN CARCINOMA

#3 | 2023-07-20
US20230226154A1
Human necessities

COMPOSITIONS AND METHODS FOR TREATING CANCER

#4 | 2022-11-17
US20220364036A1
Chemistry; metallurgy

Method of manufacturing a recombinant polypeptide

#5 | 2020-11-12
US20200354409A1
Chemistry; metallurgy

Adenoviral Polypeptide IX Increases Adenoviral Gene Therapy Vector Productivity and Infectivity

#6 | 2020-07-16
US20200222477A1
Human necessities

Method to Curtail the Progression of Non-Muscle Invasive Bladder Cancer To Muscle-Invasive Cancer

#7 | 2020-04-02
US20200101100A1
Human necessities

Transgene-Cytotoxic Combination Therapy

#8 | 2020-03-05
US20200071725A1
Chemistry; metallurgy

Nucleic acid application primers

#9 | 2019-09-26
US20190292609A1
Chemistry; metallurgy

Gene therapy vector contamination assay

#10 | 2019-09-12
US20190276846A1
Chemistry; metallurgy

Seeding An Adherent Cell Bioreactor With Non-Adherent Cells Increases Seeding Density Limit And Reduces Required Expansion Time

#11 | 2019-09-12
US20190275106A1
Human necessities

Anti-Angiogenic Gene Therapy Kit

#12 | 2019-07-18
US20190218495A1
Chemistry; metallurgy

Aseptic bioreactor sampling system

#13 | 2019-01-31
US20190031998A1
Chemistry; metallurgy

Fixed-bed bioreactor with constant-flow pump / tubing system

#14 | 2017-12-07
US20170348345A1
Human necessities

Combination Therapy For Cancer

#15 | 2017-02-23
US20170051309A1
Chemistry; metallurgy

Seeding An Adherent Cell Bioreactor With Non-Adherent Cells Increases Seeding Density Limit And Reduces Required Expansion Time

#16 | 2017-01-19
US20170016028A1
Chemistry; metallurgy

Production of Lentiviral Vectors

#17 | 2016-04-07
US20160097060A1
Chemistry; metallurgy

Production of Vectors for Non-Dividing Host Cells

#18 | 2016-03-03
US20160058888A1
Human necessities

Treatment of Operable High-Grade Glioma With Sitimagene Ceradenovec Gene Therapy and Ganciclovir

#19 | 2014-02-27
US20140057851A1
Human necessities

Anti-Angiogenic Gene Therapy With Soluble VEGF Receptors -1, -2 and -3 Together With Paclitaxel Prolongs Survival Of Mice With Human Ovarian Carcinoma

#20 | 2014-01-16
US20140017204A1
Human necessities

Transfection of Mesothelium Body Cavity Lining with Gene Agents Followed by Chemotharapy to Treat Cancer of Organs in the Body Cavity

#21 | 2014-01-16
US20140017202A1
Human necessities

Transfection of Mesothelium Body Cavity Lining with Gene Agents Followed by Chemotharapy to Treat Cancer of Organs in the Body Cavity

#22 | 2013-12-12
US20130331442A1
Human necessities

Combination Therapy for Cancer

#23 | 2013-11-21
US20130310444A1
Human necessities

Combination Therapy for Cancer

#24 | 2013-11-07
US20130296407A1
Human necessities

Combination Therapy for Cancer

#25 | 2012-12-06
US20120308522A1
Human necessities

Therapeutic Use of Growth Factor, and Delivery Device, Especially for the Treatment of Intimal Hyperplasia

#26 | 2011-06-16
US20110144013A1
Chemistry; metallurgy

VEGF-D mutants and their use

#27 | 2011-03-03
US20110052540A1
Human necessities

Non-Aggregating Virus Formulation

#28 | 2010-09-02
US20100221791A1
Chemistry; metallurgy

Method for Incorporating Proteins Into Lentivirus Vectors

#29 | 2010-01-07
US20100003746A1
Chemistry; metallurgy

Production of Lentiviral Vectors

#30 | 2009-07-09
US20090176660A1
Chemistry; metallurgy

Engineered Baculoviruses and Their Use

#31 | 2009-02-19
US20090047733A1
Chemistry; metallurgy

Avidin-Pseudotyped Viral Vectors and Their Use

#32 | 2009-01-08
US20090011984A1
Chemistry; metallurgy

Biotin-binding receptor molecules

#33 | 2009-01-08
US20090011509A1
Chemistry; metallurgy

INTEGRASE FUSION PROTEINS AND THEIR USE WITH INTEGRATING GENE THERAPY

#34 | 2008-12-11
US20080305999A1
Human necessities

Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia

#35 | 2008-11-13
US20080280783A1
Chemistry; metallurgy

Baculovirus-Based Gene Libraries

#36 | 2008-11-13
US20080280363A1
Chemistry; metallurgy

Pseudotyped Baculovirus and its Use

#37 | 2008-10-23
US20080261234A1
Chemistry; metallurgy

Peptides and their use in assays for cardiovascular disease

#38 | 2008-06-19
US20080147045A1
Chemistry; metallurgy

Use of VEGF-C or VEGF-D in Reconstructive Surgery

#39 | 2008-01-22
US10370291
-

Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia

#40 | 2007-09-27
US20070224675A1
Chemistry; metallurgy

Expression Cassette

#41 | 2007-04-24
US10618570
-

Nucleic acids encoding biotin-binding receptors

#42 | 2006-11-02
US20060246091A1
Chemistry; metallurgy

Avidin-pseudotyped viral vectors and their use

#43 | 2006-05-04
US20060093653A1
Human necessities

Periadventitial delivery device

#44 | 2005-11-17
US20050256075A1
Chemistry; metallurgy

Use of VEGF-D gene to prevent restenosis

#45 | 2005-10-25
US9427657
-

Use of VEGF-C to prevent restenosis

#46 | 2005-09-15
US20050201983A1
Chemistry; metallurgy

Engineered baculoviruses and their use

InventorID:

520175 ⎘